PHILADELPHIA – Penn Medicine researchers have singled out a bacterial enzyme behind an imbalance in the gut microbiome linked to Crohn’s disease. The new study, published online this week in Science Translational Medicine, suggests that wiping out a significant portion of the bacteria in the gut microbiome, and then re-introducing a certain type of “good” bacteria that lacks this enzyme, known as urease, may be an effective approach to better treat these diseases.
“Because it’s a single enzyme that is involved in this process, it might be a targetable solution,” said the study’s senior author, Gary D. Wu, MD, associate chief for research in the division of Gastroenterology at the Perelman School of Medicine at the University of Pennsylvania. “The idea would be that we could ‘engineer’ the composition of the microbiota in some way that lacks this particular one.”
An imbalance in the gut microbiome – more “bad” bacteria than “good” – is known as dysbiosis, which is caused by environmental stressors, such as intestinal inflammation, antibiotics, or diet. Gut dysbiosis is believed to fuel Crohn’s disease and other diseases, but the mechanisms behind that relationship is not fully understood by researchers looking to strike a healthier, bacterial balance for patients. Crohn’s disease is an inflammatory bowel disease that affects nearly one million children and adults in the United States.
In a series of human and mouse studies, the researchers discovered that a type of “bad” bacteria known as Proteobacteria feeding on urea, a waste product that can end up back in the colon, played an important role in the development of dysbiosis.
The “bad” bacteria, which harbor the urease enzyme, convert urea into ammonia (nitrogen metabolism), which is then reabsorbed by bacteria to make amino acids that are associated with dysbiosis in Crohn’s disease. “Good” bacteria may not respond in a similar manner, and thus may serve as a potential therapeutic approach to engineer the microbiome into a healthier state and treat disease.
“The study is important is because it shows that the movement of nitrogen into bacteria is an important process in the development of dysbiosis,” Wu said. “It also proves using a single enzyme can reconfigure the entire composition of the gut microbiota.”
The research was conducted by Wu and colleagues from Penn Medicine and Children’s Hospital of Philadelphia (CHOP), under the PennCHOP Microbiome Program with funding from the Crohn’s and Colitis Foundation.
To investigate the role of nitrogen metabolism in dysbiosis, the researchers performed a metabolomic analysis characterizing small molecules in fecal samples from 90 patients with Crohn’s disease from the Pediatric Longitudinal Study of Elemental Diet and Stool Microbiota Composition (PLEASE) study and 26 healthy children.
The results showed that fecal amino acids, a result of bacterial nitrogen metabolism, were significantly associated with Crohn’s disease, dysbiosis, and an abundance of Proteobacteria in patients. That led the researchers to track nitrogen metabolism activity in the mouse models to help reveal mechanisms that might be targets for the treatment of disease.
To show that urease regulated bacterial nitrogen metabolism and leads to dysbiosis, the microbiome’s slate had to be wiped clean before the microbiota could be engineered into a specific configuration. Researchers previously showed pretreating mice with antibiotics (vancomycin and neomycin) and polyethylene glycol (PEG), an intestinal purging agent used by patients in preparation for a colonoscopy, significantly reduced the bacterial load enough to create an opportunity for a newly introduced bacterial community to establish themselves.
Using this approach, in the current study, researchers showed that inoculating pre-treated mice with a single bacterial species, Escherichia coli, altered the gut microbiome in a significant way, depending on the presence of urease. Mice injected with urease-negative E. coli did not lead to dysbiosis, while mice with urease-positive E. coli did. The urease-positive E. coli also exacerbated colitis in the mice.
Similar to mice, treating five human subjects with the same two antibiotics and PEG also successfully reduced bacterial load in their intestinal tract by 100,000-fold, suggesting that it might be possible to engineer the composition of the gut microbiota in patients with inflammatory bowel disease.
“Now that we can effectively reduce bacterial load in humans it may now be possible to engineer the microbiota into a different configuration in a manner similar to what we have achieved in mice,” Wu said. “Although we’re closer now, there is still more work to be done.”
In fact, the Penn and CHOP team are currently conducting a therapeutic clinical study in patients with refractory Crohn’s disease using a strategy based on data from this study that focuses on deeply altering the gut microbiota.
“The outcomes of this study and the analysis of collected biospecimens will be an important first step in building a technology platform to engineer a beneficial composition of the gut microbiota for the treatment of inflammatory bowel diseases,” Wu said.
Patient samples for this study came from CHOP, IWK Health Center in Halifax and The Hospital for Sick Children in Toronto. Co-authors of the study include Josephine Ni, Ting-Chin David Shen, Eric Z. Chen , Kyle Bittinger, Aubrey Bailey, Manuela Roggiani, Alexandra Sirota-Madi, Elliot S. Friedman, Lillian Chau, Andrew Lin, Ilana Nissim, Justin Scott, Abigail Lauder, Christopher Hoffmann, Gloriany Rivas, Lindsey Albenberg, Robert N. Baldassano, Jonathan Braun, Ramnik J. Xavier, Clary B. Clish, Marc Yudkoff, Hongzhe Li, Mark Goulian, Frederic D. Bushman, and James D. Lewis.
The work was supported by the National Institutes of Health (P30 DK050306, UH3 DK083981, T32 DK007066, K24 DK078228, R01 GM080279 and R01 GM103591), the Crohn’s & Colitis Foundation, AGA-Takeda Pharmaceuticals Research Scholar Award in Inflammatory Bowel Disease, AGA Microbiome Junior Investigator Research Award, as well as the Penn-CHOP Microbiome Program, and the Sheila and Stanley Greenberg Fund.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.